keyword
MENU ▼
Read by QxMD icon Read
search

Biomarker AND Alzheimer's disease

keyword
https://www.readbyqxmd.com/read/28320113/alzheimer-s-disease-elevated-pigment-epithelium-derived-factor-in-the-cerebrospinal-fluid-is-mostly-of-systemic-origin
#1
Veronika Lang, Marietta Zille, Carmen Infante-Duarte, Sven Jarius, Holger Jahn, Friedemann Paul, Klemens Ruprecht, Ana Luisa Pina
Pigment-epithelium derived factor (PEDF) is a neurotrophic factor with neuroprotective, anti-tumorigenic, and anti-angiogenic effects. Elevated levels of PEDF have previously been proposed as a cerebrospinal fluid (CSF) biomarker for Alzheimer's disease. However, the origin of PEDF in CSF, i.e. whether it is derived from the brain or from the systemic circulation, and the specificity of this finding hitherto remained unclear. Here, we analyzed levels of PEDF in paired CSF and serum samples by ELISA in patients with Alzheimer's disease (AD, n=12), frontotemporal dementia (FTD, n=6), vascular dementia (n=4), bacterial meningitis (n=8), multiple sclerosis (n=32), pseudotumor cerebri (n=36), and diverse non-inflammatory neurological diseases (n=19)...
April 15, 2017: Journal of the Neurological Sciences
https://www.readbyqxmd.com/read/28319241/alzheimer-disease-signature-neurodegeneration-and-apoe-genotype-in-mild-cognitive-impairment-with-suspected-non-alzheimer-disease-pathophysiology
#2
Stefanie Schreiber, Frank Schreiber, Samuel N Lockhart, Andy Horng, Alexandre Bejanin, Susan M Landau, William J Jagust
Importance: There are conflicting results claiming that Alzheimer disease signature neurodegeneration may be more, less, or similarly advanced in individuals with β-amyloid peptide (Aβ)-negative (Aβ-) suspected non-Alzheimer disease pathophysiology (SNAP) than in Aβ-positive (Aβ+) counterparts. Objective: To examine patterns of neurodegeneration in individuals with SNAP compared with their Aβ+ counterparts. Design, Setting, and Participants: A longitudinal cohort study was conducted among individuals with mild cognitive impairment (MCI) and cognitively normal individuals receiving care at Alzheimer's Disease Neuroimaging Initiative sites in the United States and Canada for a mean follow-up period of 30...
March 20, 2017: JAMA Neurology
https://www.readbyqxmd.com/read/28317651/clinical-validity-of-presynaptic-dopaminergic-imaging-with%C3%A2-123-i-ioflupane%C3%A2-and-noradrenergic-imaging-with-123-i-mibg-in-the-differential-diagnosis-between-alzheimer-s-disease-and-dementia-with-lewy-bodies-in-the-context-of-a-structured-5-phase-development
#3
REVIEW
Ida Sonni, Osman Ratib, Marina Boccardi, Agnese Picco, Karl Herholz, Flavio Nobili, Andrea Varrone
The use of biomarkers (BMs) for accurate diagnosis of Alzheimer's disease (AD) has been proposed by recent diagnostic criteria; however, their maturity is not sufficient to grant implementation in the clinical routine. A proper diagnostic process requires not only confirmation of the disease but also the exclusion of similar disorders entering differential diagnosis, like dementia with Lewy bodies (DLB). This review is aimed at evaluating the clinical validity of (123)I-ioflupane brain single photon emission tomography and (123)I-MIBG cardiac scintigraphy as imaging BMs for DLB...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317650/clinical-validity-of-increased-cortical-uptake-of-amyloid-ligands-on-pet-as-a-biomarker-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#4
REVIEW
Konstantinos Chiotis, Laure Saint-Aubert, Marina Boccardi, Anton Gietl, Agnese Picco, Andrea Varrone, Valentina Garibotto, Karl Herholz, Flavio Nobili, Agneta Nordberg
The use of biomarkers has been proposed for diagnosing Alzheimer's disease in recent criteria, but some biomarkers have not been sufficiently investigated to justify their routine clinical use. Here, we evaluate in a literature review the clinical validity of amyloid positron emission tomography (PET) imaging using a structured framework developed for the assessment of oncological biomarkers. Homogenous criteria have been addressed in reviews of other Alzheimer's disease biomarkers. There is adequate evidence that the main aims of phases 1 (rationale for use) and 2 (discriminative ability) have been achieved...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317649/clinical-validity-of-cerebrospinal-fluid-a%C3%AE-42-tau-and-phospho-tau-as-biomarkers-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#5
REVIEW
Niklas Mattsson, Anders Lönneborg, Marina Boccardi, Kaj Blennow, Oskar Hansson
Novel diagnostic criteria for Alzheimer's disease (AD) incorporate biomarkers, but their maturity for implementation in clinical practice at the prodromal stage (mild cognitive impairment [MCI]) is unclear. Here, we evaluate cerebrospinal fluid (CSF) β-amyloid42 (Aβ42), total tau, and phosphorylated tau in the light of a 5-phase framework for biomarker development. Ample evidence is available for phase 1 (identifying useful leads) and phase 2 (assessing the accuracy for AD dementia versus controls) for CSF biomarkers...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317648/clinical-validity-of-brain-fluorodeoxyglucose-positron-emission-tomography-as-a-biomarker-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#6
REVIEW
Valentina Garibotto, Karl Herholz, Marina Boccardi, Agnese Picco, Andrea Varrone, Agneta Nordberg, Flavio Nobili, Osman Ratib
The use of Alzheimer's disease (AD) biomarkers is supported in diagnostic criteria, but their maturity for clinical routine is still debated. Here, we evaluate brain fluorodeoxyglucose positron emission tomography (FDG PET), a measure of cerebral glucose metabolism, as a biomarker to identify clinical and prodromal AD according to the framework suggested for biomarkers in oncology, using homogenous criteria with other biomarkers addressed in parallel reviews. FDG PET has fully achieved phase 1 (rational for use) and most of phase 2 (ability to discriminate AD subjects from healthy controls or other forms of dementia) aims...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317647/clinical-validity-of-medial-temporal-atrophy-as-a-biomarker-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#7
REVIEW
Mara Ten Kate, Frederik Barkhof, Marina Boccardi, Pieter Jelle Visser, Clifford R Jack, Karl-Olof Lovblad, Giovanni B Frisoni, Philip Scheltens
Research criteria for Alzheimer's disease recommend the use of biomarkers for diagnosis, but whether biomarkers improve the diagnosis in clinical routine has not been systematically assessed. The aim is to evaluate the evidence for use of medial temporal lobe atrophy (MTA) as a biomarker for Alzheimer's disease at the mild cognitive impairment stage in routine clinical practice, with an adapted version of the 5-phase oncology framework for biomarker development. A literature review on visual assessment of MTA and hippocampal volumetry was conducted with other biomarkers addressed in parallel reviews...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317646/clinical-validity-of-delayed-recall-tests-as-a-gateway-biomarker-for-alzheimer-s-disease-in-the-context-of-a-structured-5-phase-development-framework
#8
REVIEW
Chiara Cerami, Bruno Dubois, Marina Boccardi, Andreas U Monsch, Jean Francois Demonet, Stefano F Cappa
Although Alzheimer's disease criteria promote the use of biomarkers, their maturity in clinical routine still needs to be assessed. In the light of the oncology framework, we conducted a literature review on measures used to assess delayed recall impairment due to medial temporal lobe dysfunction (i.e., free and cued word list recall tests). Ample evidence is available for phases 1 (rationale for use), 2 (discriminative ability), and 3 (early detection ability) for many of the tests in routine use. Evidence about phase 4 (performance in real world) and phase 5 (quantify impact and costs) is yet to come...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317645/the-biomarker-based-diagnosis-of-alzheimer-s-disease-2-lessons-from-oncology
#9
REVIEW
Marina Boccardi, Valentina Gallo, Yutaka Yasui, Paolo Vineis, Alessandro Padovani, Urs Mosimann, Panteleimon Giannakopoulos, Gabriel Gold, Bruno Dubois, Clifford R Jack, Bengt Winblad, Giovanni B Frisoni, Emiliano Albanese
Biomarkers for the diagnosis of Alzheimer's disease (AD) are not yet validated for use in clinical settings. We aim to provide a methodological framework for their systematic validation, by reference to that developed for oncology biomarkers. As for this discipline, the steps for the systematic validation of AD biomarkers need to target analytical validity, clinical validity, and clinical utility. However, the premises are different from oncology: the nature of disease (neurodegeneration vs. cancer), the purpose (improve diagnosis in clinically affected vs...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317644/the-biomarker-based-diagnosis-of-alzheimer-s-disease-1-ethical-and-societal-issues
#10
REVIEW
Corinna Porteri, Emiliano Albanese, Charles Scerri, Maria C Carrillo, Heather M Snyder, Birgitta Martensson, Mark Baker, Ezio Giacobini, Marina Boccardi, Bengt Winblad, Giovanni B Frisoni, Samia Hurst
There is great interest in the use of biomarkers to assist in the timely identification of Alzheimer's disease (AD) in individuals with mild symptoms. However, the inclusion of AD biomarkers in clinical criteria poses socioethical challenges. The Geneva Task Force for the Roadmap of Alzheimer's Biomarkers was established to deliver a systematic strategic research agenda (aka roadmap) to promote efficient and effective validation of AD biomarkers and to foster their uptake in clinical practice. In this article, we summarize the workshop discussion of the Geneva Task Force "ethical and societal issues" working group, which comprised bioethicists, clinicians, health economists, and representatives of those affected by AD...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317643/biomarkers-for-the-diagnosis-of-alzheimer-s-disease-in-clinical-practice-an-italian-intersocietal-roadmap
#11
Giovanni B Frisoni, Daniela Perani, Stefano Bastianello, Gaetano Bernardi, Corinna Porteri, Marina Boccardi, Stefano F Cappa, Marco Trabucchi, Alessandro Padovani
Biomarkers of brain amyloidosis and neurodegeneration/synaptic dysfunction are featured in recent diagnostic criteria for Alzheimer's disease. Several gaps in our knowledge, however, need to be filled before they can be adopted clinically. The aim of this article is to describe a roadmap, developed by a multidisciplinary task force, to rationally implement biomarkers for Italian Memory Clinics. This roadmap is based on a framework comprising 5 sequential phases: identification of leads for potentially useful biomarkers; development of clinical assays for clinical disease; evaluation of detection of early stages; definition of operating characteristics in relevant populations; and estimation of reducing disease-associated mortality, morbidity, and disability...
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28317642/alzheimer-s-disease-biomarker-development-a-call-to-funding-bodies
#12
EDITORIAL
Giovanni B Frisoni, Clifford R Jack, Bengt Winblad
No abstract text is available yet for this article.
April 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28315450/phospholipid-oxidation-and-carotenoid-supplementation-in-alzheimer-s-disease-patients
#13
O S Ademowo, H K I Dias, I Milic, A Devitt, R Moran, R Mulcahy, A N Howard, J M Nolan, H R Griffiths
Alzheimer's disease (AD) is a progressive, neurodegenerative disease, characterised by decline of memory, cognitive function and changes in behaviour. Generic markers of lipid peroxidation are increased in AD, therefore reactive oxygen species have been suggested to be involved in the aetiology of cognitive decline. Carotenoids are depleted in AD serum, therefore we have compared serum lipid oxidation between AD and age-matched control subjects before and after carotenoid supplementation. The novel oxidised phospholipid biomarker 1-palmitoyl-2-(5'-oxo-valeroyl)-sn-glycero-3-phosphocholine (POVPC) was analysed using electrospray ionization tandem mass spectrometry (MS) with multiple reaction monitoring (MRM), 8-isoprostane (IsoP) was measured by ELISA and ferric reducing antioxidant potential (FRAP) was measured by a colorimetric assay...
March 14, 2017: Free Radical Biology & Medicine
https://www.readbyqxmd.com/read/28315264/the-evolution-of-the-sigma-2-%C3%AF-2-receptor-from-obscure-binding-site-to-bona-fide-therapeutic-target
#14
Chenbo Zeng, Robert H Mach
The sigma-2 (σ2) receptor represents one of the most poorly understood proteins in cell biology. Although this receptor was identified through in vitro binding studies over 25 years ago, the molecular identity of this protein is currently not unambiguously known, and the results from recent attempts to identify the σ2 receptor through protein purification and mass spectral analysis have been the subject of debate in the literature. However, there is overwhelming data demonstrating that the σ2 receptor is an important biomarker of tumor cell proliferation ...
2017: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/28314660/alzheimer-s-disease-the-next-frontier-special-report-2017
#15
Jason Karlawish, Clifford R Jack, Walter A Rocca, Heather M Snyder, Maria C Carrillo
In the history of medicine, one means to progress is when we make the decision that our assumptions and definitions of disease are no longer consistent with the scientific evidence, and no longer serve our health care needs. The arc of scientific progress is now requiring a change in how we diagnose Alzheimer's disease. Both the National Institute on Aging-Alzheimer's Association (NIA-AA) 2011 workgroup and the International Work Group (IWG) have proposed guidelines that use detectable measures of biological changes in the brain, commonly known as biological markers, or biomarkers, as part of the diagnosis...
March 14, 2017: Alzheimer's & Dementia: the Journal of the Alzheimer's Association
https://www.readbyqxmd.com/read/28314160/difference-in-imaging-biomarkers-of-neurodegeneration-between-early-and-late-onset-amnestic-alzheimer-s-disease
#16
Anne-Laure Aziz, Bernard Giusiano, Sven Joubert, Lauréline Duprat, Mira Didic, Claude Gueriot, Lejla Koric, José Boucraut, Olivier Felician, Jean-Philippe Ranjeva, Eric Guedj, Mathieu Ceccaldi
Neuroimaging biomarkers differ between patients with early-onset Alzheimer's disease (EOAD) and late-onset Alzheimer's disease (LOAD). Whether these changes reflect cognitive heterogeneity or differences in disease severity is still unknown. This study aimed at investigating changes in neuroimaging biomarkers, according to the age of onset of the disease, in mild amnestic Alzheimer's disease patients with positive amyloid biomarkers in cerebrospinal fluid. Both patient groups were impaired on tasks assessing verbal and visual recognition memory...
February 21, 2017: Neurobiology of Aging
https://www.readbyqxmd.com/read/28304304/raman-spectrometric-detection-methods-for-early-and-non-invasive-diagnosis-of%C3%A2-alzheimer-s-disease
#17
Chia-Chi Huang, Ciro Isidoro
The continuous increasing rate of patients suffering of Alzheimer's disease (AD) worldwide requires the adoption of novel techniques for non-invasive early diagnosis and monitoring of the disease. Here we review the various Raman spectroscopic techniques, including Fourier Transform-Raman spectroscopy, surface-enhanced Raman scattering spectroscopy, coherent anti-Stokes Raman scattering spectroscopy, and confocal Raman microspectroscopy, that could be used for the diagnosis of AD. These techniques have shown the potential to detect AD biomarkers, such as the amyloid-β peptide and the tau protein, or the neurotransmitters involved in the disease (e...
March 18, 2017: Journal of Alzheimer's Disease: JAD
https://www.readbyqxmd.com/read/28302766/csf-clearance-in-alzheimer-disease-measured-with-dynamic-pet
#18
Mony J de Leon, Yi Li, Nobuyuki Okamura, Wai H Tsui, Les A Saint Louis, Lidia Glodzik, Ricardo S Osorio, Juan Fortea, Tracy Butler, Elizabeth Pirraglia, Silvia Fossati, Hee-Jin Kim, Roxana O Carare, Maiken Nedergaard, Helene Benveniste, Henry Rusinek
Evidence supporting the hypothesis that reduced cerebrospinal fluid (CSF) clearance is involved in the pathophysiology of Alzheimer's disease (AD) comes from primarily from rodent models. However, unlike rodents where predominant extra-cranial CSF egress is via olfactory nerves traversing the cribriform plate, human CSF clearance pathways are not well characterized. Using dynamic Positron Emission Tomography (PET) with (18)F-THK5117 a tracer for tau pathology, the ventricular CSF time activity was used as a biomarker for CSF clearance...
March 16, 2017: Journal of Nuclear Medicine: Official Publication, Society of Nuclear Medicine
https://www.readbyqxmd.com/read/28302164/cost-effectiveness-of-cerebrospinal-biomarkers-for-the-diagnosis-of-alzheimer-s-disease
#19
Spencer A W Lee, Luciano A Sposato, Vladimir Hachinski, Lauren E Cipriano
BACKGROUND: Accurate and timely diagnosis of Alzheimer's disease (AD) is important for prompt initiation of treatment in patients with AD and to avoid inappropriate treatment of patients with false-positive diagnoses. METHODS: Using a Markov model, we estimated the lifetime costs and quality-adjusted life-years (QALYs) of cerebrospinal fluid biomarker analysis in a cohort of patients referred to a neurologist or memory clinic with suspected AD who remained without a definitive diagnosis of AD or another condition after neuroimaging...
March 16, 2017: Alzheimer's Research & Therapy
https://www.readbyqxmd.com/read/28301062/metabolomic-guided-discovery-of-alzheimer-s-disease-biomarkers-from-body-fluid
#20
REVIEW
Che Nor Adlia Enche Ady, Siong Meng Lim, Lay Kek Teh, Mohd Zaki Salleh, Ai-Vyrn Chin, Maw Pin Tan, Philip Jun Hua Poi, Shahrul Bahyah Kamaruzzaman, Abu Bakar Abdul Majeed, Kalavathy Ramasamy
The rapid increase in the older population has made age-related diseases like Alzheimer's disease (AD) a global concern. Given that there is still no cure for this neurodegenerative disease, the drastic growth in the number of susceptible individuals represents a major emerging threat to public health. The poor understanding of the mechanisms underlying AD is deemed the greatest stumbling block against progress in definitive diagnosis and management of this disease. There is a dire need for biomarkers that can facilitate early diagnosis, classification, prognosis, and treatment response...
March 16, 2017: Journal of Neuroscience Research
keyword
keyword
25364
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"